AstraZeneca

  • Daliresp 2016 report

    Daliresp 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 21 Pages The 5 Key Questions Addressed by this Report:...

  • Farxiga 2016 report

    Farxiga 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 21 Pages The 5 Key Questions Addressed by this Report:...

  • Faslodex 2016 report

    Faslodex 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 26 Pages The 5 Key Questions Addressed by this Report:...

  • Iressa 2016 report

    Iressa 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 24 Pages The 5 Key Questions Addressed by this Report:...

  • Lynparza 2016 report

    Lynparza 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 26 Pages The 5 Key Questions Addressed by this Report:...

  • Movantik 2016 report

    Movantik 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 28 Pages The 5 Key Questions Addressed by this Report:...

  • Myalept 2016 report

    Myalept 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 26 Pages The 5 Key Questions Addressed by this Report:...

  • Onglyza 2016 report

    Onglyza 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 21 Pages The 5 Key Questions Addressed by this Report:...

  • Seroquel XR 2016 report

    Seroquel XR 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 21 Pages The 5 Key Questions Addressed by this...

  • Symbicort 2016 report

    Symbicort 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 24 Pages The 5 Key Questions Addressed by this Report:...

  • Synagis 2016 report

    Synagis 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 17 Pages The 5 Key Questions Addressed by this Report:...

  • Tagrisso 2016 report

    Tagrisso 2016 U.S. PROMOTIONAL AUDIT REPORT Published July 2017 • 24 Pages The 5 Key Questions Addressed by this Report:...